News & Updates

Early-onset fever tied to severe cytokine release syndrome, multiple tocilizumab doses

29 Jan 2023

An earlier onset of fever appears to predict a more severe and progressive cytokine release syndrome, a life-threatening hyper-inflammatory state caused by immune effector cell therapy, suggests a study. Such condition also warrants several doses of anti-interleukin (IL)-6 therapy, such as tocilizumab.

Early-onset fever tied to severe cytokine release syndrome, multiple tocilizumab doses

29 Jan 2023

Pharmacist-led intervention improves BP control of patients on oral chemotherapy

28 Jan 2023

Patients on oral chemotherapy, who underwent a pharmacist-led hypertension management program, show improvements in blood pressure (BP) control as well as lower mean BP readings over time, reports a recent study.

Pharmacist-led intervention improves BP control of patients on oral chemotherapy

28 Jan 2023

Proton therapy reirradiation confers survival benefits in head and neck cancer, with caveat

27 Jan 2023

Treatment with proton therapy reirradiation for head and neck cancer appears to improve survival outcomes in patients, but this benefit comes with substantial toxic effects, according to a study.

Proton therapy reirradiation confers survival benefits in head and neck cancer, with caveat

27 Jan 2023

$Low BMD, fracture risk upped in childhood cancer survivors$

Low BMD, fracture risk upped in childhood cancer survivors

25 Jan 2023 by

Childhood cancer survivors (CCS) appear to have an increased risk of low bone mineral density (BMD) and fracture compared with the general population, according to a cross-sectional study from the Netherlands.

Low BMD, fracture risk upped in childhood cancer survivors

25 Jan 2023

Immune checkpoint inhibitors carry some risk of hepatotoxicity

25 Jan 2023

The use of immune checkpoint inhibitors (ICIs) for the treatment of various cancers appears to have hepatotoxic effects, the risk of which is greater with ICI combination therapy than with monotherapy, as reported in a recent study.

Immune checkpoint inhibitors carry some risk of hepatotoxicity

25 Jan 2023

Objective response to systemic therapy linked to overall survival in unresectable HCC

23 Jan 2023 by

Objective response to first-line systemic therapy with lenvatinib or sorafenib independently predicts overall survival (OS) in individuals with unresectable hepatocellular carcinoma (HCC), as shown by the subanalysis of the REFLECT study.

Objective response to systemic therapy linked to overall survival in unresectable HCC

23 Jan 2023

Multiple moles, genetic predisposition up risk of second primary melanomas

22 Jan 2023

Individuals with multiple nevi and high genetic predisposition to melanoma appear to have the highest risks of developing second primary melanomas, according to a study.

Multiple moles, genetic predisposition up risk of second primary melanomas

22 Jan 2023

Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC

20 Jan 2023 by

Updated results of the DESTINY-Breast03 trial, presented at SABCS 2022, showed that in patients with HER2+ metastatic breast cancer, second-line treatment with trastuzumab deruxtecan conferred better survival benefits than treatment with trastuzumab emtansine.

Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC

20 Jan 2023

TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients

20 Jan 2023

Tumour necrosis factor (TNF)-α antagonists show comparable safety as non-TNF biologics in the treatment of inflammatory bowel disease (IBD) in patients with active or recent cancer, as shown in a study.

TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients

20 Jan 2023

POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC

20 Jan 2023 by

Adding two immune checkpoint inhibitors, tremelimumab (T) and durvalumab (D), to platinum-based chemotherapy (CT) significantly improves overall survival (OS) and progression-free survival (PFS) vs CT alone in first-line treatment of metastatic non-small-cell lung cancer (mNSCLC), without causing a meaningful increase in toxicity, according to results of the phase III POSEIDON trial.

POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC

20 Jan 2023

News & Updates

Filter by Specialty:

Specialty:

Early-onset fever tied to severe cytokine release syndrome, multiple tocilizumab doses

Early-onset fever tied to severe cytokine release syndrome, multiple tocilizumab doses

Pharmacist-led intervention improves BP control of patients on oral chemotherapy

Pharmacist-led intervention improves BP control of patients on oral chemotherapy

Proton therapy reirradiation confers survival benefits in head and neck cancer, with caveat

Proton therapy reirradiation confers survival benefits in head and neck cancer, with caveat

Low BMD, fracture risk upped in childhood cancer survivors

Low BMD, fracture risk upped in childhood cancer survivors

Immune checkpoint inhibitors carry some risk of hepatotoxicity

Immune checkpoint inhibitors carry some risk of hepatotoxicity

Objective response to systemic therapy linked to overall survival in unresectable HCC

Objective response to systemic therapy linked to overall survival in unresectable HCC

Multiple moles, genetic predisposition up risk of second primary melanomas

Multiple moles, genetic predisposition up risk of second primary melanomas

Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC

Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC

TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients

TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients

POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC

POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC